cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.25975411
title: Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression

description: The use of alirocumab and evolocumab is generally safe and well-tolerated. However, concerns remain about their long-term safety, especially with regard to new-onset or worsening diabetes mellitus (DM). We aim to assess the safety profile of alirocumab and evolocumab compared to comparator. Studies were retrieved comparing the safety of PCSK9i vs. comparator (placebo or statin with or without ezetimibe). The primary outcome was adverse events leading to death. Secondary outcomes included serious adverse events, new onset diabetes mellitus (DM), worsening of DM, neurocognitive dysfunction, creatine kinase (CK) elevation, elevation of liver enzymes and local injection site reaction. Factors associated with the treatment effect were determined by meta-regression analysis. Subgroup analyses were done to explore potential treatment effect differences based on PCSK9i type and treatment duration. We identified 56 studies with 85,123 adults (29.14% females). PCSK9i was not associated with adverse events that lead to death (OR 0.94, 95% CI 0.84 to 1.04, <i>p</i> = 0.22). Between the two PCSK9i, alirocumab decreased adverse events leading to death (OR 0.79, 95% CI, 0.67 to 0.94, <i>p</i> = 0.008). PCSK9i was associated with less serious events compared to the comparator (OR 0.93, 95% CI 0.89 to 0.98, <i>p</i> &lt; 0.001). This reduction was driven mainly by alirocumab (OR 0.89, 95% CI, 0.85 to 0.93, <i>p</i> &lt; 0.001). Evolocumab worsened DM (OR 2.3, 95% CI 1.26 to 4.2, <i>p</i> = 0.041). Subgroup analysis showed worsening of DM in the first 24 weeks of treatment with odds being highest in the first 12 weeks of treatment (&lt;12 weeks: OR 3.82, 95% CI 1.13 to 12.99, <i>p</i> = 0.03; 12–24 weeks OR 2.12, 95% CI 1.20 to 3.73, <i>p</i> = 0.01. On the other hand, therapy &gt;24 weeks reduced the odds of worsening DM (OR 0.89, 95% CI 0.79 to 0.99, <i>p</i> = 0.04). PCSK9i did not increase cognitive dysfunction, (OR 1.02, 95% CI 0.88 to 1.18, <i>p</i> = 0.76), or cause elevations in liver enzyme (OR 0.91, 95% CI 0.81 to 1.03, <i>p</i> = 0.14), or CK (OR 0.82, 95% CI 0.65 to 1.04, <i>p</i> = 0.10). However, PCSK9i was associated with local injection site reaction (OR 1.54, 95% CI 1.37 to 1.73, <i>p</i> &lt; 0.01). Alirocumab decreased adverse events leading to death. Alirocumab and Evolocumab both decreased serious adverse events. PCSK9i did not increase new onset DM however evolocumab worsened DM in the first 24 weeks of treatment. PCSK9i did not increase neurologic dysfunction, and did not elevate liver enzymes and CK, however it was associated with local injection site reaction.
DOI: 10.6084/m9.figshare.25975411.v2
title: Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression

description: The use of alirocumab and evolocumab is generally safe and well-tolerated. However, concerns remain about their long-term safety, especially with regard to new-onset or worsening diabetes mellitus (DM). We aim to assess the safety profile of alirocumab and evolocumab compared to comparator. Studies were retrieved comparing the safety of PCSK9i vs. comparator (placebo or statin with or without ezetimibe). The primary outcome was adverse events leading to death. Secondary outcomes included serious adverse events, new onset diabetes mellitus (DM), worsening of DM, neurocognitive dysfunction, creatine kinase (CK) elevation, elevation of liver enzymes and local injection site reaction. Factors associated with the treatment effect were determined by meta-regression analysis. Subgroup analyses were done to explore potential treatment effect differences based on PCSK9i type and treatment duration. We identified 56 studies with 85,123 adults (29.14% females). PCSK9i was not associated with adverse events that lead to death (OR 0.94, 95% CI 0.84 to 1.04, <i>p</i> = 0.22). Between the two PCSK9i, alirocumab decreased adverse events leading to death (OR 0.79, 95% CI, 0.67 to 0.94, <i>p</i> = 0.008). PCSK9i was associated with less serious events compared to the comparator (OR 0.93, 95% CI 0.89 to 0.98, <i>p</i> &lt; 0.001). This reduction was driven mainly by alirocumab (OR 0.89, 95% CI, 0.85 to 0.93, <i>p</i> &lt; 0.001). Evolocumab worsened DM (OR 2.3, 95% CI 1.26 to 4.2, <i>p</i> = 0.041). Subgroup analysis showed worsening of DM in the first 24 weeks of treatment with odds being highest in the first 12 weeks of treatment (&lt;12 weeks: OR 3.82, 95% CI 1.13 to 12.99, <i>p</i> = 0.03; 12–24 weeks OR 2.12, 95% CI 1.20 to 3.73, <i>p</i> = 0.01. On the other hand, therapy &gt;24 weeks reduced the odds of worsening DM (OR 0.89, 95% CI 0.79 to 0.99, <i>p</i> = 0.04). PCSK9i did not increase cognitive dysfunction, (OR 1.02, 95% CI 0.88 to 1.18, <i>p</i> = 0.76), or cause elevations in liver enzyme (OR 0.91, 95% CI 0.81 to 1.03, <i>p</i> = 0.14), or CK (OR 0.82, 95% CI 0.65 to 1.04, <i>p</i> = 0.10). However, PCSK9i was associated with local injection site reaction (OR 1.54, 95% CI 1.37 to 1.73, <i>p</i> &lt; 0.01). Alirocumab decreased adverse events leading to death. Alirocumab and Evolocumab both decreased serious adverse events. PCSK9i did not increase new onset DM however evolocumab worsened DM in the first 24 weeks of treatment. PCSK9i did not increase neurologic dysfunction, and did not elevate liver enzymes and CK, however it was associated with local injection site reaction.
DOI: 10.6084/m9.figshare.25975411.v1
title: Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression

description: The use of alirocumab and evolocumab is generally safe and well-tolerated. However, concerns remain about their long-term safety, especially with regard to new-onset or worsening diabetes mellitus (DM). We aim to assess the safety profile of alirocumab and evolocumab compared to comparator. Studies were retrieved comparing the safety of PCSK9i vs. comparator (placebo or statin with or without ezetimibe). The primary outcome was adverse events leading to death. Secondary outcomes included serious adverse events, new onset diabetes mellitus (DM), worsening of DM, neurocognitive dysfunction, creatine kinase (CK) elevation, elevation of liver enzymes and local injection site reaction. Factors associated with the treatment effect were determined by meta-regression analysis. Subgroup analyses were done to explore potential treatment effect differences based on PCSK9i type and treatment duration. We identified 56 studies with 85,123 adults (29.14% females). PCSK9i was not associated with adverse events that lead to death (OR 0.94, 95% CI 0.84 to 1.04, p = 0.22). Between the two PCSK9i, alirocumab decreased adverse events leading to death (OR 0.79, 95% CI, 0.67 to 0.94, p = 0.008). PCSK9i was associated with less serious events compared to the comparator (OR 0.93, 95% CI 0.89 to 0.98, p &lt; 0.001). This reduction was driven mainly by alirocumab (OR 0.89, 95% CI, 0.85 to 0.93, p &lt; 0.001). Evolocumab worsened DM (OR 2.3, 95% CI 1.26 to 4.2, p = 0.041). Subgroup analysis showed worsening of DM in the first 24 weeks of treatment with odds being highest in the first 12 weeks of treatment (&lt;12 weeks: OR 3.82, 95% CI 1.13 to 12.99, p = 0.03; 12-24 weeks OR 2.12, 95% CI 1.20 to 3.73, p = 0.01. On the other hand, therapy &gt;24 weeks reduced the odds of worsening DM (OR 0.89, 95% CI 0.79 to 0.99, p = 0.04). PCSK9i did not increase cognitive dysfunction, (OR 1.02, 95% CI 0.88 to 1.18, p = 0.76), or cause elevations in liver enzyme (OR 0.91, 95% CI 0.81 to 1.03, p = 0.14), or CK (OR 0.82, 95% CI 0.65 to 1.04, p = 0.10). However, PCSK9i was associated with local injection site reaction (OR 1.54, 95% CI 1.37 to 1.73, p &lt; 0.01). Alirocumab decreased adverse events leading to death. Alirocumab and Evolocumab both decreased serious adverse events. PCSK9i did not increase new onset DM however evolocumab worsened DM in the first 24 weeks of treatment. PCSK9i did not increase neurologic dysfunction, and did not elevate liver enzymes and CK, however it was associated with local injection site reaction.
DOI: 10.6084/m9.figshare.25966891
title: Medical cannabis and its efficacy/effectiveness on the management of osteoarthritis pain and function

description: Despite pharmacological treatments for osteoarthritis (OA), more individuals are choosing medical cannabis for OA symptom management and for mitigating opioid prescriptions for OA. This systematic review examines the global evidence of medical cannabis use on OA pain and function. The search was completed in MEDLINE (PubMed), Embase, and CINAHL within the past 10 years (2012-2022). We limited the search to English language articles. We did not include grey literature or case studies. Participant demographics included all adult individuals with OA who were using medical cannabis for OA. Study quality and risk of bias were evaluated using the Grading of Recommendations, Assessment, Development and Evaluations framework; and the Risk of Bias in Non-randomized Studies of Interventions tool. We used a narrative synthesis approach. Overall, 7 studies were included: 2 randomized controlled trials (RCT) and 5 observational studies. Only 1 of the 2 RCTs reported improvements in pain for cannabis users. All 5 observational studies reported an improvement in pain levels, reduction of opioid use, and/or improvement in overall OA function. Despite high risk of bias ratings and low study quality, the consensus across studies was that medical cannabis use was effective for a subgroup of individuals suffering from OA pain. There is low quality evidence to support medical cannabis use as a substitute for primary pharmacological treatment of OA. However, this does not negate the observations that medical cannabis may provide therapeutic relief for a subset of patients. CRD42022354026
DOI: 10.6084/m9.figshare.25966891.v2
title: Medical cannabis and its efficacy/effectiveness on the management of osteoarthritis pain and function

description: Despite pharmacological treatments for osteoarthritis (OA), more individuals are choosing medical cannabis for OA symptom management and for mitigating opioid prescriptions for OA. This systematic review examines the global evidence of medical cannabis use on OA pain and function. The search was completed in MEDLINE (PubMed), Embase, and CINAHL within the past 10 years (2012-2022). We limited the search to English language articles. We did not include grey literature or case studies. Participant demographics included all adult individuals with OA who were using medical cannabis for OA. Study quality and risk of bias were evaluated using the Grading of Recommendations, Assessment, Development and Evaluations framework; and the Risk of Bias in Non-randomized Studies of Interventions tool. We used a narrative synthesis approach. Overall, 7 studies were included: 2 randomized controlled trials (RCT) and 5 observational studies. Only 1 of the 2 RCTs reported improvements in pain for cannabis users. All 5 observational studies reported an improvement in pain levels, reduction of opioid use, and/or improvement in overall OA function. Despite high risk of bias ratings and low study quality, the consensus across studies was that medical cannabis use was effective for a subgroup of individuals suffering from OA pain. There is low quality evidence to support medical cannabis use as a substitute for primary pharmacological treatment of OA. However, this does not negate the observations that medical cannabis may provide therapeutic relief for a subset of patients. CRD42022354026
DOI: 10.6084/m9.figshare.25780133
title: Influence of tricuspid regurgitation on the prognosis of patients with cardiogenic shock

description: Tricuspid regurgitation (TR) is associated with adverse prognosis in various patient populations. However, data regarding the prognostic impact in patients with cardiogenic shock (CS) is limited. The study investigates the prognostic impact of pre-existing TR in patients with CS. Consecutive patients with CS from 2019 to 2021 were included in a monocentric registry. Every patient’s medical history, including echocardiographic data, was recorded. The influence of pre-existing TR on prognosis was investigated. Furthermore, Kaplan–Meier analyses based on TR severity were conducted. Statistical analyses comprised univariable t-test, Spearman’s correlation, Kaplan–Meier analyses, as well as multivariable Cox proportional regression models. Analyses were stratified by the underlying cause of CS such as acute myocardial infarction (AMI), or the need for mechanical ventilation. 105 patients with CS and pre-existing TR were included. In Kaplan Meier analyses, it could be demonstrated that patients with severe TR (TR III°) had the highest 30-day all-cause mortality compared to mild (TR I°) and moderate TR (TR II°) (44% vs. 52% vs. 77%; log rank <i>p</i> = .054). In the subgroup analyses of CS-patients without AMI, TR II°/TR III° showed a higher all-cause mortality after 30 days compared to TR I° (39% vs. 64%; log rank <i>p</i> = .027). In multivariable Cox regression TR II°/TR III° was associated with 30-day all-cause mortality in CS-patients without AMI (HR = 2.193; 95% CI 1.007–4.774; <i>p</i> = .048). No significant difference could be found in the AMI group. Furthermore, TR II°/III° was linked to an increased 30-day all-cause mortality in non-ventilated CS-patients (6% vs. 50%, log rank <i>p</i> = .015), which, however, could not be confirmed in multivariable Cox regression. The occurrence of pre-existing TR II°/III° was independently related with 30-day all-cause mortality in CS-patients without AMI. However, no prognostic influence was observed in CS-patients with AMI.
DOI: 10.6084/m9.figshare.25780133.v2
title: Influence of tricuspid regurgitation on the prognosis of patients with cardiogenic shock

description: Tricuspid regurgitation (TR) is associated with adverse prognosis in various patient populations. However, data regarding the prognostic impact in patients with cardiogenic shock (CS) is limited. The study investigates the prognostic impact of pre-existing TR in patients with CS. Consecutive patients with CS from 2019 to 2021 were included in a monocentric registry. Every patient’s medical history, including echocardiographic data, was recorded. The influence of pre-existing TR on prognosis was investigated. Furthermore, Kaplan–Meier analyses based on TR severity were conducted. Statistical analyses comprised univariable t-test, Spearman’s correlation, Kaplan–Meier analyses, as well as multivariable Cox proportional regression models. Analyses were stratified by the underlying cause of CS such as acute myocardial infarction (AMI), or the need for mechanical ventilation. 105 patients with CS and pre-existing TR were included. In Kaplan Meier analyses, it could be demonstrated that patients with severe TR (TR III°) had the highest 30-day all-cause mortality compared to mild (TR I°) and moderate TR (TR II°) (44% vs. 52% vs. 77%; log rank <i>p</i> = .054). In the subgroup analyses of CS-patients without AMI, TR II°/TR III° showed a higher all-cause mortality after 30 days compared to TR I° (39% vs. 64%; log rank <i>p</i> = .027). In multivariable Cox regression TR II°/TR III° was associated with 30-day all-cause mortality in CS-patients without AMI (HR = 2.193; 95% CI 1.007–4.774; <i>p</i> = .048). No significant difference could be found in the AMI group. Furthermore, TR II°/III° was linked to an increased 30-day all-cause mortality in non-ventilated CS-patients (6% vs. 50%, log rank <i>p</i> = .015), which, however, could not be confirmed in multivariable Cox regression. The occurrence of pre-existing TR II°/III° was independently related with 30-day all-cause mortality in CS-patients without AMI. However, no prognostic influence was observed in CS-patients with AMI.
DOI: 10.6084/m9.figshare.25966891.v1
title: Medical cannabis and its efficacy/effectiveness on the management of osteoarthritis pain and function

description: Despite pharmacological treatments for osteoarthritis (OA), more individuals are choosing medical cannabis for OA symptom management and for mitigating opioid prescriptions for OA. This systematic review examines the global evidence of medical cannabis use on OA pain and function. The search was completed in MEDLINE (PubMed), Embase, and CINAHL within the past 10 years (2012-2022). We limited the search to English language articles. We did not include grey literature or case studies. Participant demographics included all adult individuals with OA who were using medical cannabis for OA. Study quality and risk of bias were evaluated using the Grading of Recommendations, Assessment, Development and Evaluations framework; and the Risk of Bias in Non-randomized Studies of Interventions tool. We used a narrative synthesis approach. Overall, 7 studies were included: 2 randomized controlled trials (RCT) and 5 observational studies. Only 1 of the 2 RCTs reported improvements in pain for cannabis users. All 5 observational studies reported an improvement in pain levels, reduction of opioid use, and/or improvement in overall OA function. Despite high risk of bias ratings and low study quality, the consensus across studies was that medical cannabis use was effective for a subgroup of individuals suffering from OA pain. There is low quality evidence to support medical cannabis use as a substitute for primary pharmacological treatment of OA. However, this does not negate the observations that medical cannabis may provide therapeutic relief for a subset of patients. CRD42022354026
DOI: 10.15468/dl.zbfg2c
title: Occurrence Download

description: A dataset containing 27556 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Nicotiana tabacum L."
 ]
}

 The dataset includes 27556 records from 598 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012989-240626123714530/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.26190182
title: e-gcloud envir.wmv

description: Cloud Platform
DOI: 10.6084/m9.figshare.26190182.v1
title: e-gcloud envir.wmv

description: Cloud Platform
DOI: 10.5281/zenodo.12655592
title: Data complementing the Avian influenza overview March - June 2024

description: Data complementing the Avian influenza overview March - June 2024

 

Annex A – Data on birds and mammals

The annex contains tables and figures on birds and mammals, including HPAI virus detections in these species.

 

Annex B – Characteristics of the HPAI A(H5Nx)-affected poultry establishments

The annex contains a table with the characteristics of the HPAI A(H5Nx)-affected poultry establishments by affected European country submitted to ADIS between 16 March and 14 June 2024.

 

Annex C – Data on virus sequences

The annex contains information on authors, originating and submitting laboratories of the sequences from GISAID's EpiFlu™ Database on which this research is based. All data submitters may be contacted directly via www.gisaid.org.

 

 
description: EU; xls; EN; BIOHAW@efsa.europa.eu
DOI: 10.5281/zenodo.12655593
title: Data complementing the Avian influenza overview March - June 2024

description: Data complementing the Avian influenza overview March - June 2024

 

Annex A – Data on birds and mammals

The annex contains tables and figures on birds and mammals, including HPAI virus detections in these species.

 

Annex B – Characteristics of the HPAI A(H5Nx)-affected poultry establishments

The annex contains a table with the characteristics of the HPAI A(H5Nx)-affected poultry establishments by affected European country submitted to ADIS between 16 March and 14 June 2024.

 

Annex C – Data on virus sequences

The annex contains information on authors, originating and submitting laboratories of the sequences from GISAID's EpiFlu™ Database on which this research is based. All data submitters may be contacted directly via www.gisaid.org.

 

 
description: EU; xls; EN; BIOHAW@efsa.europa.eu
DOI: 10.15468/dl.mgyfrh
title: Occurrence Download

description: A dataset containing 8010 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Oenanthe javanica (Blume) DC."
 ]
}

 The dataset includes 8010 records from 214 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012990-240626123714530/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.10471096
title: Output Dataset from "Stellar Atmospheric Parameters From Gaia BP/RP Spectra using Uncertain Neural Networks"

description: Output dataset of stellar parameters and associated uncertainties derived by the machine learning approach, as decribed in "Stellar Atmospheric Parameters From Gaia BP/RP Spectra using Uncertain Neural Networks", Fallows & Sanders (in prep). 

Included parameters: [Fe/H] (fe_h), effective temperature (teff), surface gravity (logg), [C/Fe] (c_fe), [N/Fe] (n_fe), and [a/M] (a_m). Gaia DR3 source ids are included for matching purposes, alongside Gaia bp_rp_excess_factor and ruwe metrics for quality filtering.

Note: the creation of this dataset is ongoing, and is currently incomplete. Parameters are available for Gaia DR3 objects between 0 deg ≤ RA ≤ 165.75 deg. The full dataset will be available soon.
DOI: 10.5281/zenodo.10573484
title: Output Dataset from "Stellar Atmospheric Parameters From Gaia BP/RP Spectra using Uncertain Neural Networks"

description: Output dataset of stellar parameters and associated uncertainties derived by the machine learning approach, as decribed in "Stellar Atmospheric Parameters From Gaia BP/RP Spectra using Uncertain Neural Networks", Fallows & Sanders (in prep). 

Included parameters: [Fe/H] (fe_h), effective temperature (teff), surface gravity (logg), [C/Fe] (c_fe), [N/Fe] (n_fe), and [a/M] (a_m). Gaia DR3 source ids are included for matching purposes, alongside Gaia bp_rp_excess_factor and ruwe metrics for quality filtering.

We include predictions for only Gaia objects with radial velocity measurements ('output_0.0_360.0_v2.txt'), and for all Gaia objects with XP spectra (coming soon).
DOI: 10.5281/zenodo.10471095
title: Output Dataset from "Stellar Atmospheric Parameters From Gaia BP/RP Spectra using Uncertain Neural Networks"

description: Output dataset of stellar parameters and associated uncertainties derived by the machine learning approach, as decribed in "Stellar Atmospheric Parameters From Gaia BP/RP Spectra using Uncertain Neural Networks", Fallows & Sanders (2024). 

Included parameters: [Fe/H] (fe_h), effective temperature (teff), surface gravity (logg), [C/Fe] (c_fe), [N/Fe] (n_fe), and [a/M] (a_m). Gaia DR3 source ids are included for matching purposes, alongside Gaia bp_rp_excess_factor and ruwe metrics for quality filtering.

We include predictions for only Gaia objects with radial velocity measurements ('output_0.0_360.0_v2.txt'), and for all* Gaia objects with XP spectra ('gaiaFull_output_0.0_360.0.zip'). Note our full catalogue has a total size of 30.9GB once uncompressed.

 

* Not truly all objects with XP spectra; stars with spurious or unreliable measurements in our requred inputs (Gaia, 2MASS, WISE) have been removed.